Shares of Perspective Therapeutics, Inc. (NYSE:CATX – Get Free Report) have been assigned an average rating of “Buy” from the seven ratings firms that are presently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $20.00.
A number of brokerages recently issued reports on CATX. Oppenheimer reaffirmed an “outperform” rating on shares of Perspective Therapeutics in a research report on Tuesday, June 18th. Bank of America began coverage on shares of Perspective Therapeutics in a research report on Thursday, July 25th. They set a “buy” rating and a $24.00 target price on the stock. Lifesci Capital reaffirmed an “outperform” rating on shares of Perspective Therapeutics in a research report on Monday, May 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $30.00 target price on shares of Perspective Therapeutics in a research report on Friday, June 14th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research report on Tuesday, June 25th.
View Our Latest Report on CATX
Insider Activity
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the business. Rhumbline Advisers bought a new position in shares of Perspective Therapeutics in the second quarter valued at about $630,000. Bank of New York Mellon Corp raised its holdings in shares of Perspective Therapeutics by 214.0% in the second quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company’s stock valued at $1,369,000 after buying an additional 93,548 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Perspective Therapeutics in the first quarter valued at about $138,000. Janus Henderson Group PLC bought a new position in shares of Perspective Therapeutics in the first quarter valued at about $15,511,000. Finally, Affinity Asset Advisors LLC bought a new position in shares of Perspective Therapeutics in the first quarter valued at about $6,069,000. 54.66% of the stock is owned by institutional investors.
Perspective Therapeutics Price Performance
NYSE:CATX opened at $12.29 on Friday. Perspective Therapeutics has a 12 month low of $2.05 and a 12 month high of $19.05. The company has a debt-to-equity ratio of 0.01, a quick ratio of 12.98 and a current ratio of 12.98. The company has a 50 day moving average price of $12.15.
Perspective Therapeutics (NYSE:CATX – Get Free Report) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.10. The firm had revenue of $0.33 million during the quarter. Sell-side analysts forecast that Perspective Therapeutics will post -1.02 EPS for the current year.
Perspective Therapeutics Company Profile
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Featured Stories
- Five stocks we like better than Perspective Therapeutics
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Roth IRA Calculator: Calculate Your Potential Returns
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- How to invest in marijuana stocks in 7 steps
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.